Tamoxifen treatment for precocious puberty in McCune-Albright syndrome: a multicenter trial
- PMID: 12915825
- DOI: 10.1016/S0022-3476(03)00128-8
Tamoxifen treatment for precocious puberty in McCune-Albright syndrome: a multicenter trial
Abstract
Objective: We undertook a 1-year multicenter trial of tamoxifen treatment for precocious puberty in girls with McCune-Albright syndrome (MAS).
Study design: Girls < or =10 years with classic or atypical MAS were recruited. Pretreatment history was collected for 6 months. Patients received 20 mg tamoxifen daily. Diaries were used to record bleeding. Evaluations included physical examination, bone age, pelvic ultrasound, hormone levels, and safety assessments.
Results: A total of 28 girls (2.9-10.9 years of age) were enrolled from 20 centers, of whom 25 completed 12 months of tamoxifen treatment. Compared with before the study, vaginal bleeding episodes decreased (3.42+/-3.36/year vs 1.17+/-1.41/year), growth velocity slowed (SDS 1.22+/-2.65 vs -0.59+/-3.06, P=.005), and rate of bone maturation decreased (1.21+/-0.78 vs 0.72+/-0.36, P=.02). Ovarian volumes were enlarged and asymmetric throughout the study, and uterine volumes were increased. No adverse events occurred.
Conclusions: Tamoxifen treatment of precocious puberty in MAS results in a reduction of vaginal bleeding and significant improvements in growth velocity and rate of skeletal maturation.
Comment in
-
Precocious puberty: McCune-Albright syndrome and beyond.J Pediatr. 2003 Jul;143(1):9-10. doi: 10.1016/S0022-3476(03)00272-5. J Pediatr. 2003. PMID: 12915816 No abstract available.
Similar articles
-
Treatment of precocious puberty in the McCune-Albright syndrome with the aromatase inhibitor testolactone.N Engl J Med. 1986 Oct 30;315(18):1115-9. doi: 10.1056/NEJM198610303151802. N Engl J Med. 1986. PMID: 3093862
-
Effective aromatase inhibition by anastrozole in a patient with gonadotropin-independent precocious puberty in McCune-Albright syndrome.J Pediatr Endocrinol Metab. 2002;15 Suppl 3:945-8. J Pediatr Endocrinol Metab. 2002. PMID: 12199354
-
Diagnosis and management of precocious puberty in atypical presentations of McCune-Albright syndrome: a case series review.J Pediatr Adolesc Gynecol. 2012 Feb;25(1):e9-e13. doi: 10.1016/j.jpag.2011.09.005. Epub 2011 Nov 3. J Pediatr Adolesc Gynecol. 2012. PMID: 22051789
-
Tamoxifen improved final height prediction in a girl with McCune-Albright syndrome: patient report and literature review.J Pediatr Endocrinol Metab. 2006 Jan;19(1):81-6. doi: 10.1515/jpem.2006.19.1.81. J Pediatr Endocrinol Metab. 2006. PMID: 16509532 Review.
-
Pubertal development in patients with McCune-Albright syndrome or pseudohypoparathyroidism.J Pediatr Endocrinol Metab. 2003 Mar;16 Suppl 2:293-6. J Pediatr Endocrinol Metab. 2003. PMID: 12729407 Review.
Cited by
-
[Efficacy and safety of letrozole in treatment of McCune-Albright syndrome girls with peripheral precocious puberty].Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(3):291-296. doi: 10.3785/j.issn.1008-9292.2020.04.03. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020. PMID: 32762164 Free PMC article. Chinese.
-
Effect of Tamoxifen and Lithium on Treatment of Acute Mania Symptoms in Children and Adolescents.Iran J Child Neurol. 2016 Spring;10(2):16-25. Iran J Child Neurol. 2016. PMID: 27247580 Free PMC article.
-
Fulvestrant treatment of precocious puberty in girls with McCune-Albright syndrome.Int J Pediatr Endocrinol. 2012 Sep 22;2012(1):26. doi: 10.1186/1687-9856-2012-26. Int J Pediatr Endocrinol. 2012. PMID: 22999294 Free PMC article.
-
The Clinical Spectrum of McCune-Albright Syndrome and Its Management.Horm Res Paediatr. 2019;92(6):347-356. doi: 10.1159/000504802. Epub 2019 Dec 19. Horm Res Paediatr. 2019. PMID: 31865341 Free PMC article. Review.
-
Fibrous Dysplasia/McCune-Albright Syndrome: A Rare, Mosaic Disease of Gα s Activation.Endocr Rev. 2020 Apr 1;41(2):345-70. doi: 10.1210/endrev/bnz011. Endocr Rev. 2020. PMID: 31673695 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
